Related Experiment Videos
Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy
A Beydoun1, T Fakhoury, W Nasreddine
1Department of Neurology, University of Michigan Medical Center, Ann Arbor 48109, USA.
Epilepsia
|May 13, 1998
Summary
High-dose gabapentin (GBP) monotherapy up to 4,800 mg/day effectively reduced seizures in some patients with refractory partial epilepsy. This treatment was generally well-tolerated, with tiredness/sleepiness being the most common side effect.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Epilepsy is a chronic neurological disorder characterized by recurrent seizures.
- Medically refractory epilepsy often requires exploring alternative treatment strategies.
- Gabapentin (GBP) is an anticonvulsant medication with established efficacy in epilepsy management.
Purpose of the Study:
- To assess the safety and efficacy of high-dose gabapentin (GBP) monotherapy (3,000–4,800 mg/day).
- To evaluate GBP's effectiveness in patients with partial epilepsy that is resistant to other treatments.
Main Methods:
- Open-label phase of a double-blind trial involving GBP monotherapy up to 4,800 mg/day.
- Assessment of adverse events and seizure frequency reduction compared to baseline.
- Correlation analysis of GBP serum levels, dosage, and seizure change.
Main Results:
- 23 out of 45 patients (51%) successfully transitioned to GBP monotherapy (average dose 3,900 mg/day).
- Significant reductions in simple partial (54%), complex partial (43%), and generalized seizures (14%) were observed.
- High-dose GBP monotherapy was well-tolerated, with tiredness/sleepiness as the most frequent adverse event.
Conclusions:
- High-dose gabapentin (GBP) monotherapy (up to 4,800 mg/day) is safe and effective for a subset of patients with medically refractory partial epilepsy.
- The treatment demonstrates a favorable safety profile, with manageable side effects.